Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Creo Medical ( (GB:CREO) ) has provided an update.
Creo Medical Group has appointed Shore Capital Stockbrokers as joint corporate broker, alongside existing broker and nominated adviser Deutsche Numis, strengthening its advisory and capital markets support. The move underscores the company’s efforts to bolster its market presence as it advances commercialisation of its CROMA-powered electrosurgical platform for minimally invasive endoscopic cancer procedures.
By adding a second broker, Creo is broadening its access to investors and potentially enhancing liquidity in its AIM-listed shares, which may support future financing and growth initiatives. The expanded broking line-up aligns with the company’s strategy to leverage its adaptive Kamaptive energy technology to reshape surgical and endoscopic practice with safer, less invasive and more cost-efficient solutions.
The most recent analyst rating on (GB:CREO) stock is a Buy with a £16.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.
Spark’s Take on GB:CREO Stock
According to Spark, TipRanks’ AI Analyst, GB:CREO is a Neutral.
The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.
To see Spark’s full report on GB:CREO stock, click here.
More about Creo Medical
Creo Medical Group is a U.K.-listed medical device company specialising in minimally invasive surgical endoscopy for pre-cancer and cancer patients. It develops and commercialises electrosurgical devices enabled by its CROMA platform powered by Kamaptive technology, which integrates multi-modal energy sources to improve precision, flexibility and patient outcomes in endoscopic procedures.
Average Trading Volume: 944,748
Technical Sentiment Signal: Sell
Current Market Cap: £68.57M
See more insights into CREO stock on TipRanks’ Stock Analysis page.